NCT01493024 is a Phase 2 clinical trial of Zirconium silicate (ZS) in Hyperkalemia, sponsored by ZS Pharma, Inc..

Who is sponsoring NCT01493024?

NCT01493024 is sponsored by ZS Pharma, Inc..

What drugs are being tested in NCT01493024?

Interventions in NCT01493024: Zirconium silicate (ZS), Placebo.

What condition does NCT01493024 study?

NCT01493024 studies Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction.

Is NCT01493024 still recruiting?

NCT01493024 is currently completed. Last updated 29 June 2018.

Are results published for NCT01493024?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-06-29 · How we verify

NCT01493024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

Completed Phase 2 Results posted Last updated 29 June 2018

What this trial tests

Phase 2 trial testing Zirconium silicate (ZS) in Hyperkalemia in 90 participants. Completed in 30 June 2012.

Timeline

30 November 2011

Primary endpoint
31 May 2012

30 June 2012

Quick facts

Lead sponsor	ZS Pharma, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	90
Start date	30 November 2011
Primary completion	31 May 2012
Estimated completion	30 June 2012
Sites	9 locations across United States

Drugs / interventions tested

Zirconium silicate (ZS) — full drug profile →
Placebo

Conditions studied

Hyperkalemia — all drugs for Hyperkalemia →
Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Kidney Dysfunction — all drugs for Kidney Dysfunction →

Sponsor

ZS Pharma, Inc. — full company profile →

Who can join

18 and older, any sex, with Hyperkalemia or Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Difference in the Exponential Rate of Change in Serum Potassium (S-K) Levels Versus Placebo During the Initial 48 Hours of Study Drug Treatment Primary · 24 and 48 hours post first study drug dose

The rate of fall in S-K levels during the initial 48 hours of study drug treatment between the placebo treated subjects and the ZS treated subjects measured on a log scale

Day2/0 Hr ( 24 hours)

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	0	± NA
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	-0.00035	± 0.001166
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	-0.00169	± 0.000932
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	-0.000143	± 0.000932

Day 3/0 Hr (48 hours)

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	0	± NA
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	-0.00045	± 0.000555
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	-0.00089	± 0.000444
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	-0.00256	± 0.000444

Serum Potassium (S-K) at Individual Time Points. Secondary · First 48 hours of study

Serum potassium (S-K) at individual time points through Study day 3/0hour.

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	5.14	± 0.358
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	5.22	± 0.264
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	5.02	± 0.322
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	5.05	± 0.359

Day 1/4Hr Post 1st Dose

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	4.97	± 0.564
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	5.06	± 0.417
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.93	± 0.518
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.80	± 0.466

Day 1/4Hr Post 2nd Dose

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	4.91	± 0.465
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	5.14	± 0.609
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.80	± 0.543
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.68	± 0.420

Day 1/4Hr Post 3rd Dose

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	4.82	± 0.558
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	4.91	± 0.368
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.68	± 0.577
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.50	± 0.397

Day 2/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	4.97	± 0.521
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	4.90	± 0.447
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.66	± 0.434
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.73	± 0.463

Day 2/4Hr Post 1st Dose

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	5.03	± 0.441
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	4.97	± 0.363
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.81	± 0.601
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.53	± 0.411

Day 2/4Hr Post 2nd Dose

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	5.02	± 0.426
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	5.04	± 0.417
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.72	± 0.604
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.43	± 0.460

Day 2/4Hr Post 3rd Dose

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	4.87	± 0.486
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	4.83	± 0.526
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	4.60	± 0.566
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	4.13	± 0.388

Time Specific S-K Levels to Normalization Secondary · 48 and 72 hours post first study drug dose

Percent of subjects achieving S-K normalization (\<=as defined by S-K levels of 3.5 to 4.9 mmol/L) from baseline at Study Days 2 and 3 at 0 hr.

Day2/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	90
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	75
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	95.8
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	100

Day 3/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	90
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	100
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	95.8
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	100

Time Specific Decreases in S-K Levels of > = 0.5 mmol/L Secondary · 24 and 48 hours post first study drug dose

Percentage of participants achieving a 0.5mmol/L drop from baseline at Study Days 2 and 3 at 0 hr.

Day 2/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	16.7
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	33.3
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	37.5
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	33.3

Day 3/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	26.7
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	41.7
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	41.7
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	62.5

Percentage of Participants With Normal S-K Levels at End of Study Day 2 Secondary · 48 hours post first study drug dose

Percentage (%) of subjects who achieve S-K normalization at end of Study Day 2

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	90
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	75
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	95.8
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	100

Urine Sodium Excretion Secondary · 24 and 48 hours post first study drug dose

Urine sodium excretion compared between the combined placebo-treated controls and the ZS-treated subjects (measured throughout two 24-hour periods on Study Days 1 and 2).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	91.5	± 30.31
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	73.5	± 29.79
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	81.7	± 33.16
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	74.5	± 34.20

Day 1/0-24Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	74.4	± 24.8
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	66.7	± 18.49
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	66.8	± 26.26
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	67.1	± 29.19

Day 2/24-48Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	80.1	± 28.21
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	67.5	± 26.63
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	71.6	± 31.61
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	75.8	± 35.74

Urine Potassium Excretion Secondary · 24 and 48 hours post study drug dose

Urine potassium excretion compared between the combined placebo-treated controls and the ZS-treated subjects (measured throughout two 24-hour periods on Study Days 1 and 2).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	36.6	± 12.47
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	32.2	± 2.12
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	38.3	± 11.82
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	30.3	± 15.81

Day1/0-24Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	28.7	± 6.41
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	32.0	± 3.16
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	30.6	± 5.96
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	19.7	± 9.69

Day2/24-48Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	29.2	± 6.42
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	31.0	± 0.00
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	30.5	± 6.51
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	16.9	± 8.80

Urea Nitrogen Excretion Secondary · 24 and 48 hours post study drug dose

Urea nitrogen excretion compared between the combined placebo-treated controls and the ZS-treated subjects (measured throughout two 24-hour periods on Study Days 1 and 2).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	525.0	± 219.79
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	430.2	± 162.92
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	481.0	± 198.92
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	424.7	± 171.88

Day1/ 0-24 HR

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	389.2	± 179.91
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	401.8	± 265.74
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	414.1	± 177.54
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	368.5	± 147.37

Day2/ 24-48 HR

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	460.9	± 175.09
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	337.6	± 115.06
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	477.0	± 157.04
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	416.6	± 219.56

Blood Urea Nitrogen Secondary · 24 and 48 hours post study drug dose

Blood urea nitrogen compared between the combined placebo-treated controls and the ZS-treated subjects (measured 24 \& 48 hours post dose on Study Days 2 and 3).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	24.50	± 7.481
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	23.52	± 8.217
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	25.16	± 8.065
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	30.37	± 8.092

Day 2/)0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	24.05	± 7.626
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	23.63	± 7.241
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	23.98	± 7.619
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	27.53	± 7.602

Day 3/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	24.50	± 7.284
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	23.33	± 7.895
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	24.04	± 7.661
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	25.60	± 7.942

Serum Magnesium (S-Mg) Levels Secondary · 24 and 48 hours post study drug dose

Serum magnesium compared between the combined placebo-treated controls and the ZS-treated subjects (measured at 24 \& 48 hours post dose on Study Days 2 and 3).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	1.93	± 0.258
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	1.95	± 0.327
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	1.93	± 0.143
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	1.85	± 0.235

Day 2/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	1.92	± 0.197
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	1.93	± 0.271
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	1.94	± 0.182
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	1.81	± 0.225

Day 3/0Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	1.90	± 0.204
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	1.89	± 0.257
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	1.94	± 0.179
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	1.83	± 0.218

Serum Calcium (S-Ca) Levels Secondary · 24 and 48 hours post study drug dose

Serum calcium compared between the combined placebo-treated controls and the ZS-treated subjects (measured at 24 \& 48 hours post dose on Study Days 2 and 3).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	9.46	± 0.595
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	9.37	± 0.341
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	9.48	± 0.337
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	9.50	± 0.469

Day 2/0 Hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	9.39	± 0.439
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	9.36	± 0.507
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	9.33	± 0.388
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	9.22	± 0.466

Day 3/0 hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	9.51	± 0.544
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	9.33	± 0.360
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	9.30	± 0.397
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	9.05	± 0.425

Serum Sodium (S-Na) Levels Secondary · 24 and 48 hours post study drug dose

Serum sodium compared between the combined placebo-treated controls and the ZS-treated subjects (measured at 24 \& 48 hours post dose on Study Days 2 and 3).

Baseline

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	139.4	± 2.84
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	139.1	± 3.65
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	140.0	± 3.09
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	137.7	± 3.45

Day 2/0 hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	140.1	± 3.24
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	138.8	± 2.04
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	140.1	± 3.83
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	138.6	± 3.37

Day 3/0 hr

Group	Value	95% CI
Placebo (Combined All Three Cohorts)	140.0	± 3.36
Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily	138.5	± 2.28
Sodium Zirconium Cyclosilicate 3 g Three Times Daily	140.0	± 3.91
Sodium Zirconium Cyclosilicate 10 g Three Times Daily	139.6	± 3.50

Adverse events — posted to ClinicalTrials.gov

Time frame: Study Days 1 to 7. Reporting threshold: 3%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 0/30 (0%)

Deaths: 0/30

Sodium Zirconium Cyclosilicate (ZS) 0.3 g Three Times Daily

Serious: 0/12 (0%)

Deaths: 0/12

Sodium Zirconium Cyclosilicate 3 g Three Times Daily

Serious: 0/24 (0%)

Deaths: 0/24

Sodium Zirconium Cyclosilicate 10 g Three Times Daily

Serious: 0/24 (0%)

Deaths: 0/24

Other adverse events (13 terms — click to expand)

Reaction	System	Placebo	Sodium Zirconium Cyclosili…	Sodium Zirconium Cyclosili…	Sodium Zirconium Cyclosili…
Vomiting	Gastrointestinal disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—
Diarrhea	Gastrointestinal disorders	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—
Aspartate aminotransferae increased	Investigations	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—
Abdominal tenderness	Gastrointestinal disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—

Data from ClinicalTrials.gov NCT01493024 adverse events section.

Sponsor's own description

It is hypothesized that zirconium silicate is safe and well tolerated and more effective than placebo (alternative hypothesis) in lowering serum potassium levels in subjects with serum potassium between 5 - 6.0 mmol/l versus no difference between zirconium silicate and placebo (null hypothesis). It is hypothesized that zirconium silicate even up to the top dose of 10g three times a day is well tolerated.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Characterization of structure and function of ZS-9, a K+ selective ion trap.
Stavros F, Yang A, Leon A, Nuttall M, et al · · 2014 · cited 131× · PMID 25531770 · DOI 10.1371/journal.pone.0114686
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
Ash SR, Singh B, Lavin PT, Stavros F, et al · · 2015 · cited 120× · PMID 25651363 · DOI 10.1038/ki.2014.382
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P, Palmer SC, Ruospo M, Saglimbene VM, et al · · 2020 · cited 30× · PMID 32588430 · DOI 10.1002/14651858.cd013165.pub2
Patient and Public Involvement (PPI) in outcome selection in breast cancer and nephrology trials.
Buckley C, Treweek S, Laidlaw L, Shiely F. · · 2023 · cited 2× · PMID 36747232 · DOI 10.1186/s13063-022-06980-9

Verify or expand the search:

Other recruiting trials for Hyperkalemia

Currently open trials in the same condition.

NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
NCT06884267 — Hyperkalemia Quality Improvement Program (HK-QIP) Study · NA · recruiting
NCT06940414 — Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community · recruiting
NCT05766839 — Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age · Phase 2 · recruiting
NCT06365684 — Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 · Phase 4 · recruiting

Other ZS Pharma, Inc. trials

Trials by the same sponsor.

NCT02607085 — REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study · completed
NCT02609841 — POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study · completed
NCT02163499 — Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months · Phase 3 · completed
NCT02107092 — Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. · Phase 3 · completed
NCT02088073 — Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01493024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ZS Pharma, Inc.
Last refreshed: 29 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01493024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01493024

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Hyperkalemia

Other ZS Pharma, Inc. trials

Verify against primary sources